Studie zum Vergleich von Zanubrutinib + Rituximab mit Bendamustin + Rituximab bei Teilnehmern mit unbehandeltem Mantelzell-Lymphom (MANGROVE)
Eine randomisierte, offene, multizentrische Phase-3-Studie zum Vergleich von Zanubrutinib (BGB-3111) plus Rituximab versus Bendamustin plus Rituximab bei Patienten mit zuvor unbehandeltem Mantelzell-Lymphom, die für eine Stammzelltransplantation nicht in Frage kommen
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australien, 2605
- Canberra Hospital
-
-
New South Wales
-
Concord, New South Wales, Australien, 2139
- Concord Repatriation General Hospital
-
Cudgen, New South Wales, Australien, 2487
- The Tweed Valley Hospital
-
Darlinghurst, New South Wales, Australien, 2010
- Saint Vincents Hospital Sydney
-
Gosford, New South Wales, Australien, 2250
- Gosford Hospital
-
Waratah, New South Wales, Australien, 2298
- Calvary Mater Newcastle
-
-
Queensland
-
Birtinya, Queensland, Australien, 4575
- Sunshine Coast Hospital and Health Service
-
South Brisbane, Queensland, Australien, 4101
- Icon Cancer Foundation
-
-
South Australia
-
Bedford PK, South Australia, Australien, 5042
- Flinders Medical Centre
-
-
Tasmania
-
Hobart, Tasmania, Australien, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Monash Health
-
Fitzroy, Victoria, Australien, 3065
- St Vincents Hospital Melbourne
-
Frankston, Victoria, Australien, 3199
- Peninsula Private Hospital
-
Geelong, Victoria, Australien, 3220
- Barwon Health the Geelong Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6000
- Royal Perth Hospital
-
-
-
-
-
Bruges, Belgien, 8000
- Az Sint Jan Brugge
-
Brussels, Belgien, 1090
- Universitair Ziekenhuis Brussel
-
Edegem, Belgien, 2650
- Uz Antwerpen
-
Kortrijk, Belgien, 8500
- Az Groeninge Campus Loofstraat
-
Liège, Belgien, 4000
- Centre Hospitalier Universitaire (Chu) de Liege Site Du Sart Tilman
-
Yvoir, Belgien, 5530
- Centre Hospitalier Universitaire Universite Catholique de Louvain Site Godinne
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100044
- Peking University Peoples Hospital
-
Beijing, Beijing Municipality, China, 100050
- Beijing Friendship Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Fujian Medical University Union Hospital
-
Quanzhou, Fujian, China, 362000
- Quanzhou First Affliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Provincial Peoples Hospital
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital of Southern Medical University
-
Guangzhou, Guangdong, China, 510060
- Sun Yat Sen University Cancer Center
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
-
Xuzhou, Jiangsu, China, 221000
- The Affiliated Hospital of Xuzhou Medical University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- The First Affiliated Hospital of Nanchang University Branch Donghu
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
Changchun, Jilin, China, 130021
- Jilin Cancer Hospital
-
-
Liaoning
-
Shenyang, Liaoning, China, 110004
- Shengjing Hospital of China Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Fudan University Shanghai Cancer Center
-
Shanghai, Shanghai Municipality, China, 200120
- Shanghai East Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital, Sichuan University
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Tianjin Municipality, China, 300020
- Institute of Hematology and Hospital of Blood Disease
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830000
- Affiliated Cancer Hospital of Xinjiang Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Ningbo, Zhejiang, China, 315000
- Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)
-
-
-
-
-
Cologne, Deutschland, 50937
- Uniklinik Koln (Aor)
-
Heidelberg, Deutschland, 69120
- Universitatsklinikum Heidelberg
-
Munich, Deutschland, 81377
- Dept of Medicine Iii, University Hospitallmu
-
Ulm, Deutschland, 89081
- Universitaetsklinikum Ulm, Innere Medizin Iii
-
Wuppertal, Deutschland, 42283
- Petrus Krankenhaus Wuppertal
-
-
-
-
-
Bordeaux, Frankreich, 33076
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
Brest, Frankreich, 29200
- Chru de Brest Hospital Morvan
-
Dijon, Frankreich, J4V 2H1
- Chu Dijon
-
Grenoble, Frankreich, 38043
- Chu Grenoble Alpes
-
Le Mans, Frankreich, 72037
- Centre Hospitalier Le Mans
-
Lille, Frankreich, 59000
- Hopital Claude Huriez Chu Lille
-
Marseille, Frankreich, 13009
- Institut Paoli Calmettes
-
Nantes, Frankreich, 44093
- Centre Hospitalier Universitaire Nantes Hotel Dieu
-
Paris, Frankreich, 75005
- Institut Curie
-
Paris, Frankreich, 75015
- Necker University Hospital
-
PierreBenite, Frankreich, 69495
- Chu Hopital Lyon Sud
-
Poitiers, Frankreich, 86000
- Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
-
Quimper, Frankreich, 29000
- Ch Cornouaille
-
Toulouse, Frankreich, 31059
- Iuc Toulouse Oncopole
-
-
-
-
-
Cork, Irland, t12DC4A
- Cork University Hospital
-
Dublin, Irland, D7
- Mater Misericordiae University Hospital
-
Dublin, Irland, D8
- St Jamess Hospital
-
Galway, Irland, H91 YR71
- University Hospital Galway
-
Limerick, Irland, V94F858
- University Hospital Limerick
-
Waterford, Irland, X91 ER8E
- University Hospital Waterford
-
-
-
-
-
Alessandria, Italien, 15121
- Azienda Ospedaliera Nazionale Ssantonio E Biagio E Cesare Arrigo
-
Bologna, Italien, 40138
- Policlinico Sorsola Malpighi, Aou Di Bologna
-
Genova, Italien, 16132
- Azienda Ospedaliera Universitaria San Martino
-
Milan, Italien, 20162
- Niguarda Cancer Center Division of Hematology
-
Novara, Italien, 28100
- Aou Maggiore Della Carita
-
Palermo, Italien, 90146
- Aoor Villa Sofia Cervello
-
Pisa, Italien, 56126
- Aou Pisana, Stabilimento Di Santa Chiara
-
Ravenna, Italien, 48121
- Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
-
Reggio Emilia, Italien, 42123
- Azienda Unita Sanitaria Locale Irccs
-
Roma, Italien, 00161
- Universita Degli Studi La Sapienza
-
Siena, Italien, 53100
- Aou Senese Policlinico Santa Maria Alle Scotte
-
Torino, Italien, 10126
- Ao Citta Della Salute E Della Scienza Di Torino Presidio O
-
Verona, Italien, 37142
- University of Verona
-
-
-
-
-
Yokohama, Japan, 221-0855
- Yokohama Municipal Citizens Hospital
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Toyohashi, Aichi-ken, Japan, 441-8570
- Toyohashi Municipal Hospital
-
-
Chiba
-
Chiba, Chiba, Japan, 260-8717
- Chiba Cancer Center
-
-
Fukuoka
-
Kurume, Fukuoka, Japan, 830-0011
- Kurume University Hospital
-
-
Hiroshima
-
Hiroshima, Hiroshima, Japan, 730-8619
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Kanagawa Cancer Center
-
-
Kumamoto
-
Kumamoto, Kumamoto, Japan, 860-0008
- National Hospital Organization Kumamoto Medical Center
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Okayama-ken
-
Kurashikishi, Okayama-ken, Japan, 710-8602
- Kurashiki Central Hospital
-
Okayama, Okayama-ken, Japan, 701-1192
- National Hospital Organization Okayama Medical Center
-
-
Osaka
-
Osaka, Osaka, Japan, 545-8586
- Osaka Metropolitan University Hospital
-
Osakashi, Osaka, Japan, 543-8555
- Osaka Red Cross Hospital
-
-
Tokyo
-
Chuoku, Tokyo, Japan, 104-0045
- National Cancer Center Hospital
-
Tokyo, Tokyo, Japan, 113-8519
- Tokyo Medical and Dental University Hospital
-
-
-
-
Ontario
-
Ottawa, Ontario, Kanada, K1H 8M2
- The Ottawa Hospital
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Ciusss de Lestrie Chus
-
-
-
-
-
Christchurch, Neuseeland, 8011
- Christchurch Hospital (Canterbury Health Laboratories)
-
Tauranga, Neuseeland, 3112
- Tauranga Hospital
-
-
-
-
-
Goes, Niederlande, 4462 RA
- Admiraal de Ruijter Ziekenhuis
-
Groningen, Niederlande, 9713 GZ
- University of Medical Center Groningen (Umcg)
-
Nieuwegein, Niederlande, 3435 CM
- St Antonius Ziekenhuis, Randd Interne Geneeskunde (F)
-
Nijmegen, Niederlande, 6525 GA
- Albert Schweitzer Ziekenhuis
-
Rotterdam, Niederlande, 3015 GD
- Erasmus Mc
-
The Hague, Niederlande, 2545 CH
- Hagaziekenhuis
-
-
-
-
-
Bydgoszcz, Polen, 85-168
- Szpital Uniwersytecki Nr Im Dr Jana Biziela
-
Chorzów, Polen, 41-503
- Silesian Healthy Blood Clinic
-
Gdansk, Polen, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Gdask, Polen, 80-219
- Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
-
Gdynia, Polen, 81-519
- Szpitale Pomorskie Spolka Z Ograniczona Odpowiedzialnoscia
-
Krakow, Polen, 30-727
- Pratia McM Krakow
-
Legnica, Polen, 59-220
- Wojewodzki Szpital Specjalistyczny W Legnicy
-
Lodz, Polen, 93-510
- Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin, Polen, 20-090
- Centrum Onkologii Ziemi Lubelskiej
-
Warsaw, Polen, 02-776
- Instytut Hematologii I Transfuzjologii W Warszawie
-
Wałbrzych, Polen, 58-309
- Specjalistyczny Szpital Im Dr Alfreda Sokolowskiego
-
Wroclaw, Polen, 50-556
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Lisbon, Portugal, 1099-023
- Instituto Portugues Oncologia de Lisboa Francisco Gentil, Epe
-
Lisbon, Portugal, 1649-035
- Chuln Hospital de Santa Maria
-
Porto, Portugal, 4099-001
- Centro Hospitalar Universitario Porto
-
Porto, Portugal, 4200-072
- Instituto Portugues de Oncologia Do Porto Francisco Gentil, Epe
-
-
-
-
-
Bucharest, Rumänien, 022328
- Institutul Clinic Fundeni
-
Iași, Rumänien, 700483
- Institutul Regional de Oncologie Iasi
-
-
-
-
-
Moscow, Russland, 142770
- Gbuz Mmcc Kommunarka Dzm
-
-
Moscow
-
Moscow, Moscow, Russland, 125284
- Clinical Hospital, Sp Botkin
-
-
Sankt-Peterburg
-
Saint Petersburg, Sankt-Peterburg, Russland, 191024
- Fgu Russian Scientific Research Institute of Hematology and Transfusiology
-
Saint Petersburg, Sankt-Peterburg, Russland, 194291
- Leningrad Regional Clinic and Hospital
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitario Vall Dhebron
-
Barcelona, Spanien, 08916
- Ico Hug Trias I Pujol
-
Barcelona, Spanien, 08908
- Institut Catala Doncologia
-
Girona, Spanien, 17007
- Ico Girona
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Madrid, Spanien, 28040
- Start Madrid Fundacion Jimenez Diaz
-
Madrid, Spanien, 28033
- Md Anderson Cancer Center Madrid Spain
-
Madrid, Spanien, 28009
- Hospital Universitario Gregorio Maranon
-
Málaga, Spanien, 29010
- Hospital Regional Universitario de Malaga
-
Seville, Spanien, 41013
- Hospital Universitario Virgen Del Rocio
-
-
-
-
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Tainan, Taiwan, 736
- Chi Mei Hospital Liouying
-
Taipei, Taiwan, 114
- Tri Service General Hospital
-
-
-
-
-
Ankara, Türkei (türkiye), 06620
- Dr Abdurrahman Yurtaslan Oncology Teaching and Research Hospital
-
Ankara, Türkei (türkiye), 6500
- Gazi University
-
Ankara, Türkei (türkiye), 06700
- Hematoloji Ve Hematolik Onkoloji Tani Ve Tedavi Merezi
-
Edirne, Türkei (türkiye), 22030
- Tr Trakya University Health Research and Application Center (Hospital)
-
Istanbul, Türkei (türkiye), 34365
- Vkv American Hospital
-
Mersin, Türkei (türkiye), 33000
- Mersin Universitesi Tip Fakultesi Hastanesi
-
-
-
-
-
Cherkasy, Ukraine, 18009
- Cherkasy Regional Oncology Dispensary
-
Dnipro, Ukraine, 49102
- Municipal Non Profit Enterprise City Clinical Hospital
-
Kiev, Ukraine, 3022
- National Cancer Institute
-
Lviv, Ukraine, 79044
- Si Institute of Blood Pathology and Transfusion Medicine Nams of Ukraine, Hematology Department
-
-
-
-
California
-
Orange, California, Vereinigte Staaten, 92868
- Chao Family Comprehensive Cancer Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215-5400
- Beth Israel Deaconess Medical Center (Bidmc)
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- University of Michigan Health System
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89169
- Comprehensive Cancer Centers of Nevada
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Icahn School of Medicine At Mount Sinai
-
Westbury, New York, Vereinigte Staaten, 11590
- Clinical Research Alliance, Inc
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- West Penn Hospital
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- The University of Texas Md Anderson Cancer Center
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Seattle Cancer Care Alliance
-
-
-
-
-
Abergavenny, Vereinigtes Königreich, NP7 7EG
- Aneurin Bevan University Health Board
-
Birmingham, Vereinigtes Königreich, B9 5SS
- Birmingham Heartlands Hospital
-
Dudley, Vereinigtes Königreich, DY1 2HQ
- Russells Hall Hopsital
-
Sutton, Vereinigtes Königreich, SM2 5PT
- Royal Marsden Nhs Foundation Royal Marsden Hospital
-
-
-
-
-
Linz, Österreich, 4020
- Ordensklinikum Linz Gmbh Elisabethinen
-
Salzburg, Österreich, 5020
- Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
-
Vienna, Österreich, 1090
- Medical University Vienna Oncology
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- ≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
- Histologically confirmed diagnosis of MCL
- No prior systemic treatments for MCL
- Measurable disease by CT/MRI
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Adequate marrow and organ function
Key Exclusion Criteria:
- Known central nervous system involvement by lymphoma
- Participants for whom the goal of therapy is tumor debulking prior to stem cell transplant
- Clinically significant cardiovascular disease
- History of severe bleeding disorder
- Unable to swallow capsules or disease significantly affecting gastrointestinal function
- Active fungal, bacterial and/or viral infection requiring systemic therapy
- Requires ongoing treatment with a strong CYP3A inhibitor or inducer
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Arm A: zanubrutinib plus rituximab
Participants will receive zanubrutinib plus rituximab, followed by zanubrutinib monotherapy until Independent Review Committee (IRC)-confirmed disease progression. |
Administered as two 80 mg capsules by mouth twice a day
Andere Namen:
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6 |
|
Aktiver Komparator: Arm B: bendamustine plus rituximab
Participants will receive bendamustine plus rituximab, followed by observation. |
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6 Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6 |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free survival (PFS) determined by independent central review
Zeitfenster: Up to approximately 7 years
|
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first. |
Up to approximately 7 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PFS by investigator assessment
Zeitfenster: Up to approximately 7 years
|
PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first. |
Up to approximately 7 years
|
|
Overall response rate (ORR)
Zeitfenster: Up to approximately 7 years
|
ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), determined by independent central review and by investigator assessment. |
Up to approximately 7 years
|
|
Duration of response (DOR)
Zeitfenster: Up to approximately 7 years
|
DOR, as determined by independent central review and by investigator assessment, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first. |
Up to approximately 7 years
|
|
Overall survival (OS)
Zeitfenster: Up to approximately 7 years
|
OS is defined as the time from randomization to the date of death due to any reason. |
Up to approximately 7 years
|
|
Time to Response (TTR)
Zeitfenster: Up to approximately 7 years
|
TTR, as determined by independent central review and by investigator assessment, and defined as the time from randomization to the first documentation of response. |
Up to approximately 7 years
|
|
Rate of complete response (CR) or complete metabolic response
Zeitfenster: Up to approximately 7 years
|
Rate of CR or complete metabolic response is defined as the percentage of participants who achieve a CR or complete metabolic response, determined by independent central review and by investigator assessment. |
Up to approximately 7 years
|
|
Participant-reported outcomes (PROs) as assessed by the European Quality of Life 5-Dimension 5 Level Questionnaire (EQ-5D-5L)
Zeitfenster: Up to approximately 7 years
|
EuroQoL-Five Dimensions, Five Levels (EQ-5D-5L) is a generic, self-reported measure of utility that consists of a five-item descriptive system and a visual analogue scale (EQ VAS). The descriptive system involves five health dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Participants may choose from the following response levels: no problems=1; slight problems=2; moderate problems=3; severe problems=4; and unable to/extreme problems=5. Higher values indicate worst health. |
Up to approximately 7 years
|
|
PROs as assessed by the European Organization for Research on Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Zeitfenster: Up to approximately 7 years
|
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). |
Up to approximately 7 years
|
|
Number of participants with adverse events and serious adverse events
Zeitfenster: Up to approximately 7 years
|
Number of participants with adverse events and serious adverse events, including laboratory values, vital signs, and physical examination findings. |
Up to approximately 7 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Study Director, BeOne Medicines
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom
- Hämische und lymphatische Krankheiten
- Lymphom, Non-Hodgkin
- Lymphom, Mantelzelle
- Aminosäuren, Peptide und Proteine
- Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen
- Benzimidazoles
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Kohlenwasserstoffe
- Säuren, acyclisch
- Carboxylsäuren
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Butyate
- Antikörper, monoklonale, murine abgeleitete
- Bendamustinhydrochlorid
- Rituximab
- Zanubrutinib
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- BGB-3111-306
- 2019-000413-36 (EudraCT-Nummer)
- CTR20211594 (Registrierungskennung: ChinaDrugTrials)
- 2023-509908-15-00 (Ctis)
- 2023 (US NIH Stipendium/Vertrag)
- 2019 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD-Sharing-Zeitrahmen
See plan description
IPD-Sharing-Zugriffskriterien
See plan description
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .